Ensavatatug

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against discoid domain receptor type 1 (DDR1), with potential immunomodulating and antineoplastic activities. Upon administration, ensavatatug specifically targets, binds to and blocks DDR1, a protein expressed on tumor cells that binds collagen to make a minimally permeable physical barrier that blocks immune cells in the tumor microenvironment (TME) from interacting with and attacking the tumor. By blocking DDR1, ensavatatug causes the collagen fibers to lose alignment and loosen. This creates gaps in the tumor barrier, thereby allowing cytotoxic T-cells to enter and attack the tumor.

**Synonyms:** - Anti-DDR1 Monoclonal Antibody PRTH-101 - ENSAVATATUG - PRTH 101 - PRTH-101 - PRTH101